Editorial Commentary
Two-year analysis of CodeBreaK 100 phase I/II trial: achieved goals of an ongoing challenge
AME Clinical Trials Review
2023;
1:
20
(25 December 2023)
Editorial Commentary
What is the most optimal postoperative chest tube placement method after lung resection?
AME Clinical Trials Review
2023;
1:
19
(25 December 2023)
Editorial Commentary
Tunnel vision: seeking to reduce peritubular leakage after lung resection
AME Clinical Trials Review
2023;
1:
18
(25 December 2023)
Editorial Commentary
The opening gambit: CheckMate 159 and the immunotherapy neoadjuvant era in non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
17
(25 December 2023)
Editorial Commentary
EMPOWER Lung-3 Part 2: empowering options for anti-PD-1 and chemotherapy in non-small cell lung cancer with current landscape and remaining challenges
AME Clinical Trials Review
2023;
1:
16
(25 December 2023)
Editorial Commentary
Improving patient selection through tumor genomic recharacterization to overcome resistance to targeted therapy: commentary on the final analysis of the INSIGHT trial
AME Clinical Trials Review
2023;
1:
15
(25 December 2023)
Editorial Commentary
The importance of long-term safety, tolerability, and health-related quality of life: lessons from the ADAURA trial
AME Clinical Trials Review
2023;
1:
14
(25 December 2023)
Editorial Commentary
Pafolacianine for imaging of pulmonary neoplasms: a promising supplement for modern surgical technique
AME Clinical Trials Review
2023;
1:
13
(25 December 2023)
Editorial Commentary
Encorafenib and binimetinib as a new regimen for BRAF mutant non-small cell lung cancer
AME Clinical Trials Review
2023;
1:
12
(25 December 2023)
Editorial
A tale of two lung-sparing surgeries: the rise of segmentectomy and wedge resection in stage IA non-small-cell lung cancer
AME Clinical Trials Review
2023;
1:
11
(25 December 2023)